Preferred Label : luspatercept;
UNII : AQK7UBA1LS;
Origin ID : C000621232;
UMLS CUI : C4086553;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3490841/fr/reblozyl-luspatercept-anemie-associee-a-une-beta-thalassemie
2024
false
false
false
France
evaluation of the transparency committee
beta-Thalassemia
luspatercept
---
https://ansm.sante.fr/tableau-marr/luspatercept
2023
false
false
false
France
French
guidelines for drug use
risk management
luspatercept
luspatercept
luspatercept
injections, subcutaneous
hematinics
hematinics
pregnancy
breast feeding
continuity of patient care
patient education handout
checklist
Female of Childbearing Potential
product surveillance, postmarketing
contraception
---
https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
anemia
beta-Thalassemia
blood transfusion
Transfusion dependent anaemia
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
injections, subcutaneous
hematinics
luspatercept
evaluation of the transparency committee
luspatercept
Reblozyl
immunoglobulin fc fragments
recombinant fusion proteins
activin receptors, type ii
---
https://www.has-sante.fr/jcms/p_3281443/fr/reblozyl-luspatercept-syndrome-myelodysplasique-smd
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Reblozyl
luspatercept
myelodysplastic syndromes
anemia
adult
hematinics
luspatercept
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
injections
blood transfusion
Transfusion dependent anaemia
---
https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
luspatercept
luspatercept
luspatercept
hematinics
hematinics
orphan drug production
anemia
myelodysplastic syndromes
beta-Thalassemia
injections, subcutaneous
product surveillance, postmarketing
Transfusion dependent anemia
adult
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
immunoglobulin fc fragments
recombinant fusion proteins
activins
immunoglobulin fc fragments
recombinant fusion proteins
activins
---
